# Salubris Biotherapeutics

> Salubris Biotherapeutics (SalubrisBio) is a clinical-stage biotechnology company in Gaithersburg, Maryland that engineers complex biologics for diseases with few good options - chiefly heart failure and cancer. Founded in 2016 as the US arm of China's Shenzhen Salubris Pharmaceuticals, its lead candidate JK07 is an antibody-fusion protein designed to harness the regenerative NRG-1/ErbB4 pathway in failing hearts while dialing out the side effects, and its oncology programs JK08 and JK06 pursue solid tumors through immune engagement and a 5T4-targeted biparatopic antibody-drug conjugate.

- **Founded:** 2016
- **Headquarters:** Gaithersburg, Maryland, United States
- **Founders:** John Li (Founder, President & CEO (founding); now leadership/board), Samuel (Sam) Murphy (Co-founder; Chief Executive Officer)
- **Team size:** ~40 employees
- **Products:** JK07, JK08, JK06
- **Notable:** Advanced lead candidate JK07 into a Phase 2 heart-failure trial (RENEU-HF), enrolling first patient in 2024., Secured European Medicines Agency approval to initiate a Phase 1 trial of JK06 in solid tumors (2024)., Reported objective tumor responses across five tumor types for JK06 in early clinical cohorts.

## Products & services

- **JK07** — Lead candidate. A recombinant antibody-fusion protein pairing a fully human IgG1 monoclonal antibody with an active fragment of the growth factor neuregulin-1 (NRG-1). It is engineered to block ErbB3 signaling while selectively stimulating the regenerative ErbB4 pathway, aiming to restore cardiac function in heart failure. In the Phase 2 RENEU-HF study (HFrEF/HFpEF, ~282 patients) and explored in neurology.
- **JK08** — An IL-15 / CTLA-4 antibody-fusion protein for solid tumors. Combines a CTLA-4 antibody with an IL-15 domain to enhance natural killer (NK) cell activity and reverse tumor immunosuppression. In Phase 1b/2, including combination studies with pembrolizumab.
- **JK06** — A first-in-class quadrivalent, biparatopic antibody-drug conjugate targeting 5T4, an oncofetal protein overexpressed across many solid tumors, with an MMAE payload. The biparatopic design gives picomolar affinity and enhanced internalization. Advanced from preclinical into Phase 1/2 dose-escalation and expansion across multiple tumor types.

## Achievements

- Advanced lead candidate JK07 into a Phase 2 heart-failure trial (RENEU-HF), enrolling first patient in 2024.
- Secured European Medicines Agency approval to initiate a Phase 1 trial of JK06 in solid tumors (2024).
- Reported objective tumor responses across five tumor types for JK06 in early clinical cohorts.
- Presented JK06 dose-escalation and expansion data at major oncology meetings (ESMO 2025, AACR, ASCO).
- Raised roughly $102M total to fund three distinct clinical-stage programs with a ~40-person team.

## Latest updates

- **2026-05** — Presented updated JK06 expansion-cohort data at the American Society for Clinical Oncology (ASCO).
- **2026-04** — Presented JK06 expansion-cohort data at the American Association for Cancer Research (AACR) annual meeting.
- **2025-10** — Announced JK06 dose-escalation data at the ESMO 2025 Congress.
- **2025-09** — Provided clinical updates on the JK07 and JK06 programs.
- **2024-08** — Received EMA approval to start a Phase 1 trial of JK06 (5T4-targeted ADC) in solid tumors.
- **2024-04** — Announced $35M financing and pipeline progress; first patient enrolled in JK07 Phase 2.

## Links

- Website: https://salubrisbio.com
- LinkedIn: http://www.linkedin.com/company/salubris-biotherapeutics

---

Profile page: https://yespress.io/salubris-biotherapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-06-12